Premium
Total and free tissue factor pathway inhibitor in pregnancy hypertension
Author(s) -
Abdel Gader A.M.,
AlMishari A.A.,
Awadalla S.A.,
Buyuomi N.M.,
Khashoggi T.,
AlHakeem M.
Publication year - 2006
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2006.07.014
Subject(s) - medicine , pregnancy , eclampsia , tissue factor pathway inhibitor , preeclampsia , tissue factor , coagulation , endocrinology , obstetrics , genetics , biology
Objective To clarify the role played by tissue factor pathway inhibitor (TFPI) in pregnancy hypertension. Methods Using enzyme‐linked immunosorbent assays, hemostatic measurements were obtained for women with pre‐eclampsia ( n = 51), nonproteinuric hypertension of pregnancy ( n = 62), postpartum pre‐eclampsia 24 h after childbirth ( n = 31), and no hypertension (healthy pregnant controls, n = 100). Results There was a significant increase in circulating free TFPI levels in women with pre‐eclampsia (9.7 ± 6.2 ng/mL) or nonproteinuric hypertension of pregnancy (8.3 ± 5.3 ng/mL) compared with healthy controls (5.3 ± 2.1 ng/mL). In women with pre‐eclampsia the levels remained elevated after placental delivery (10.6 ± 4.0 ng/mL). Free protein S levels were significantly higher in women with pre‐eclampsia (40.0% ± 10.7%), nonproteinuric hypertension of pregnancy (37.1% ± 12.5%), or postpartum pre‐eclampsia (39.3% ± 9.1%) than in healthy pregnant controls (32.2% ± 8.5%). Conclusion Increased levels of the physiologically active free forms of TFPI and free protein S, 2 coagulation inhibitors, may protect women with pregnancy‐induced hypertension from the risks of hemostatic activation.